PD	Parkinson’s Disease
BBs	Beta-blockers
Ds	Diuretics
CCBs	Calcium-channel blockers
VGCCs	Voltage-gated calcium channels
HVA	High voltage-activation
LVA	Low voltage-activation
BBB	Blood-brain barrier
ACEIs	Angiotensin-converting enzyme inhibitors
ARBs	Angiotensin receptor blockers
RAAS	Renin-angiotensin-aldosterone system
H&Y	Hoehn and Yahr
UPDRS	Unified Parkinson’s Disease Rating Scale
RCT	Randomized controlled trial
OR	Odds ratio
CI	Confidence interval
HR	Hazard ratio
RR	Risk
ADRB2	Adrenoreceptor β2 gene
SNCA	α-synuclein gene
TIMP	Tissue inhibitor of metalloproteinase
MMP	Metalloproteinase
COX2	Cyclooxygenase 2
MAPK	Mitogen-activated protein kinase
ERK	Extracellular signal-regulated kinase
NO	Nitric Oxide synthase
GABA	Gamma-Aminobutyric acid
JNK	c-Jun N-terminal kinase
ROCK	Rho kinase
NOX	Nicotinamide adenine dinucleotide phosphate oxidase complex
6-OHDA	6-hidroxy dopamine
HCN	Hyperpolarization and cyclic nucleotide-activated cation
GRADE	Grading of Recommendations, Assessment, Development and Evaluation